For instance, patients with NSCLC harboring sensitizing EGFR-mutations documented before the beginning of first-line therapy should receive Erlotinib, Gefitinib, or Afatinib instead of standard chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.